PRMT1 regulates glioblastoma stemness and immunosuppression via nitric oxide metabolism: Multi-cohort analysis and experimental validation

Nitric Oxide 2026 Open access

Read full text
Authors: Kun Xue, Ya Gao, Caifeng Ma, Shuo Tang, Xinru Tian, Yang Kong, Haiying Wang
DOI: 10.1016/j.niox.2026.02.003
Cited by: 1
References: 34

Abstract

Glioblastoma is the most common primary malignant brain tumor with poor prognosis. The immunosuppressive microenvironment and cancer stem cells (CSCs) drive therapeutic resistance. The role of nitric oxide (NO) metabolism in coordinating glioma stemness and immune evasion remains unclear. We performed multi-omics analysis using CGGA, TCGA, and Rembrandt datasets (n=1,500) and single-cell RNA sequencing (n=65,655 cells). PRMT1 was identified as a key NO metabolism-associated prognostic gene through Cox regression and LASSO modeling. Validation used glioma cell lines, patient-derived GSCs, and orthotopic mouse models. NO metabolism activity increased with glioma grade and correlated with poor survival (p

Fields of Study & Subjects

Cancer-related gene regulation Nuclear Receptors and Signaling Epigenetics and DNA Methylation

Publication details

Journal / source
Nitric Oxide
Publisher
Elsevier BV
Volume
162
Pages
9–24
Publication date
24 February 2026
Language
EN